busulfan has been researched along with Cancer of Ovary in 49 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma." | 7.66 | Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). ( Ernst, P; Ersbøl, J; Hou-Jensen, K; Knudtzon, S; Larsen, MS; Nissen, NI; Pedersen-Bjergaard, J; Rose, C; Sørensen, HM, 1980) |
| "From 1977 until 1980, 179 patients with newly diagnosed FIGO stages IIB, III or IV ovarian adenocarcinoma were randomized in a two-armed clinical trial: dihydroxybusulfan (B) 600 mg/m2 p." | 5.05 | A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. ( Aabo, K; Dombernowsky, P; Hald, I; Hansen, HH; Hørbov, S; Lundvall, F; Nielsen, NC; Sørensen, BL; Sørensen, HM, 1985) |
| "In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma." | 3.72 | The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. ( Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004) |
| "Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma." | 3.66 | Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). ( Ernst, P; Ersbøl, J; Hou-Jensen, K; Knudtzon, S; Larsen, MS; Nissen, NI; Pedersen-Bjergaard, J; Rose, C; Sørensen, HM, 1980) |
| "or i." | 2.77 | A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. ( Belau, A; Fuxius, S; Heidrich-Lorsbach, E; Heuser, T; Klare, P; Kölbl, H; Mahner, S; Markmann, S; Oskay-Özcelik, G; Ruhmland, B; Sehouli, J; Sommer, H, 2012) |
| "The majority of patients with ovarian cancer are not cured by first-line treatment." | 2.70 | Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. ( Bauknecht, T; Costa, S; du, BA; Emon, G; Jackisch, C; Lück, HJ; Meier, W; Moebus, V; Olbricht, S; Richter, B; Schroeder, W; Wagner, U, 2002) |
| "Chlorambucil and melphalan were the most leukemogenic drugs, followed by thiotepa; cyclophosphamide and treosulfan were the weakest leukemogens, and the effect per gram was substantially lower at high doses than at lower doses." | 2.67 | Leukemia following chemotherapy for ovarian cancer. ( Bell, J; Clarke, EA; Day, NE; Høst, H; Kaldor, JM; Karjalainen, S; Mehnert, W; Pedersen, D; Pettersson, F; Prior, P, 1990) |
| "However, most women (75%) with advanced epithelial ovarian cancer (EOC) will relapse following surgery and chemotherapy." | 2.53 | Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. ( Lane, G; Montes, A; Seshadri, S; Wuntakal, R, 2016) |
| "Busulfan has been investigated widely for more than three decades leading to a large and precise handling of this agent with numerous studies on activity and pharmacokinetics and pharmacodynamics." | 2.49 | Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. ( Galaup, A; Paci, A, 2013) |
| "Two hundred and forty-eight ovarian cancer patients in 57 Centers, who received treosulfan mainly either i." | 1.42 | Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study. ( Ammon, A; Becker, M; Chekerov, R; Göhler, T; Heidrich-Lorsbach, E; Hutzschenreuter, U; Kaltenecker, G; Klare, P; Oskay-Özcelik, G; Reichert, D; Sauer, U; Sehouli, J; Vehling-Kaiser, U; Wischnik, A, 2015) |
| "The chemosensitivity of ovarian cancer to drugs is related to the expression of genes involved in sensitivity and resistance mechanisms." | 1.36 | Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy. ( Cree, IA; Gabriel, FG; Glaysher, S; Johnson, P; Knight, LA; Narayanan, A; Parker, K; Polak, M; Poole, M, 2010) |
| "We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16-35 months after high-dose chemotherapy (HDC) with treosulfan (47 and 56 g/m(2) body-surface area (BSA)) given as 3-25 h infusions and followed by autologous peripheral blood stem cell (PBSC) transplantation." | 1.32 | Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. ( Bojko, P; Dirsch, O; Hilger, RA; Ruehm, SG; Scheulen, ME; Seeber, S, 2003) |
| " Pharmacokinetic analyses of treosulfan were carried on plasma and urine samples from 20 i." | 1.31 | Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. ( Baumgart, J; Hilger, RA; Jacek, G; Kredtke, S; Oberhoff, C; Scheulen, ME; Seeber, S, 2000) |
| " To our knowledge, this is one of the few cases of ROC in which partial remissions using conventionally dosed chemotherapy were achieved repeatedly despite a unfavorable relapse-free interval after high-dose chemotherapy for primary disease." | 1.31 | Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. ( Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT, 2002) |
| "Busulfan 16 mg/kg was paired with cyclophosphamide 200 mg/kg (BuCY) or with etoposide 60 mg/kg (Bu-Vp)." | 1.29 | Busulfan-containing pre-transplant regimens for the treatment of solid tumors. ( Adler, SS; Feingold, JM; Ghalie, R; Kaizer, H; Korenblit, AD; Manson, S; Pruett, J; Reynolds, J; Valentino, LA, 1994) |
| "Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow." | 1.27 | Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (44.90) | 18.7374 |
| 1990's | 10 (20.41) | 18.2507 |
| 2000's | 11 (22.45) | 29.6817 |
| 2010's | 5 (10.20) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Olesen, KD | 1 |
| Larsen, ATR | 1 |
| Jensen, LH | 1 |
| Steffensen, KD | 1 |
| Søndergaard, SR | 1 |
| Chekerov, R | 1 |
| Kaltenecker, G | 1 |
| Reichert, D | 1 |
| Göhler, T | 1 |
| Klare, P | 2 |
| Oskay-Özcelik, G | 2 |
| Sauer, U | 1 |
| Wischnik, A | 1 |
| Vehling-Kaiser, U | 1 |
| Becker, M | 1 |
| Hutzschenreuter, U | 1 |
| Ammon, A | 1 |
| Heidrich-Lorsbach, E | 2 |
| Sehouli, J | 2 |
| Wuntakal, R | 1 |
| Seshadri, S | 1 |
| Montes, A | 1 |
| Lane, G | 1 |
| Meier, W | 3 |
| du Bois, A | 1 |
| Reuss, A | 1 |
| Kuhn, W | 1 |
| Olbricht, S | 2 |
| Gropp, M | 2 |
| Richter, B | 2 |
| Lück, HJ | 2 |
| Kimmig, R | 1 |
| Pfisterer, J | 1 |
| Markman, M | 1 |
| Glaysher, S | 2 |
| Gabriel, FG | 1 |
| Johnson, P | 2 |
| Polak, M | 1 |
| Knight, LA | 3 |
| Parker, K | 1 |
| Poole, M | 1 |
| Narayanan, A | 1 |
| Cree, IA | 3 |
| Mahner, S | 1 |
| Fuxius, S | 1 |
| Sommer, H | 1 |
| Belau, A | 1 |
| Ruhmland, B | 1 |
| Heuser, T | 1 |
| Kölbl, H | 1 |
| Markmann, S | 1 |
| Galaup, A | 1 |
| Paci, A | 1 |
| Di Nicolantonio, F | 2 |
| Neale, MH | 1 |
| Lamont, A | 1 |
| Skailes, GE | 1 |
| Osborne, RJ | 1 |
| Allerton, R | 1 |
| Kurbacher, CM | 2 |
| Bojko, P | 1 |
| Hilger, RA | 2 |
| Ruehm, SG | 1 |
| Dirsch, O | 1 |
| Seeber, S | 2 |
| Scheulen, ME | 2 |
| MOORE, JG | 1 |
| BRANDKAMP, WW | 1 |
| BURNES, WL | 1 |
| LOPESCARDOZO, E | 1 |
| CONKLIN, JW | 1 |
| UPTON, AC | 1 |
| CHRISTENBERRY, KW | 1 |
| Whitehouse, P | 1 |
| Mercer, S | 1 |
| Sharma, S | 1 |
| Soegaard Andersen, E | 1 |
| Knudsen, A | 1 |
| Svarrer, T | 1 |
| Lund, B | 1 |
| Nielsen, K | 1 |
| Grove, A | 1 |
| Tetsche, M | 1 |
| Reed, NS | 1 |
| Poole, CJ | 1 |
| Coleman, R | 1 |
| Parkin, D | 1 |
| Graham, JD | 1 |
| Kaye, SB | 1 |
| Ostrowski, J | 1 |
| Duncan, I | 2 |
| Paul, J | 1 |
| Hay, A | 1 |
| Burnett, RD | 1 |
| Marsh, BT | 1 |
| Grönroos, M | 1 |
| Nieminen, U | 1 |
| Kauppila, A | 1 |
| Kauppila, O | 1 |
| Saksela, E | 1 |
| Väyrynen, M | 1 |
| Cornbleet, MA | 1 |
| Leonard, RC | 1 |
| Smyth, JF | 1 |
| Thigpen, JT | 1 |
| Vance, RB | 1 |
| Balducci, L | 1 |
| Khansur, T | 1 |
| Pedersen-Bjergaard, J | 2 |
| Nissen, NI | 2 |
| Sørensen, HM | 3 |
| Hou-Jensen, K | 1 |
| Larsen, MS | 2 |
| Ernst, P | 1 |
| Ersbøl, J | 1 |
| Knudtzon, S | 1 |
| Rose, C | 1 |
| Khalil, A | 1 |
| Ciobanu, N | 1 |
| Sparano, JA | 1 |
| Gucalp, R | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 1 |
| Ghalie, R | 1 |
| Reynolds, J | 1 |
| Valentino, LA | 1 |
| Manson, S | 1 |
| Korenblit, AD | 1 |
| Feingold, JM | 1 |
| Adler, SS | 1 |
| Pruett, J | 1 |
| Kaizer, H | 1 |
| Schiffman, KS | 1 |
| Bensinger, WI | 2 |
| Appelbaum, FR | 2 |
| Rowley, S | 2 |
| Lilleby, K | 1 |
| Clift, RA | 1 |
| Weaver, CH | 1 |
| Demirer, T | 2 |
| Sanders, JE | 1 |
| Petersdorf, S | 1 |
| Gooley, T | 1 |
| Weiden, P | 2 |
| Zuckerman, N | 2 |
| Montgomery, P | 2 |
| Maziarz, R | 2 |
| Klarnet, JP | 1 |
| Rivkin, S | 2 |
| Trueblood, K | 1 |
| Storb, R | 1 |
| Holmberg, L | 1 |
| Buckner, CD | 2 |
| Keldsen, N | 1 |
| Madsen, EL | 1 |
| Havsteen, H | 1 |
| Kamby, C | 1 |
| Laursen, L | 1 |
| Sandberg, E | 1 |
| Petty, R | 1 |
| Evans, A | 1 |
| Kurbacher, C | 1 |
| Cree, I | 1 |
| Hepp, H | 1 |
| Holmberg, LA | 1 |
| Goodman, G | 1 |
| Klarnet, J | 1 |
| Harrer, G | 1 |
| McCloskey, R | 1 |
| Gersh, R | 1 |
| Goldberg, R | 1 |
| Nichols, W | 1 |
| Jacobs, A | 1 |
| Jacek, G | 1 |
| Oberhoff, C | 1 |
| Kredtke, S | 1 |
| Baumgart, J | 1 |
| Thigpen, T | 1 |
| du, BA | 1 |
| Emon, G | 1 |
| Moebus, V | 1 |
| Schroeder, W | 1 |
| Costa, S | 1 |
| Bauknecht, T | 1 |
| Jackisch, C | 1 |
| Wagner, U | 1 |
| Breidenbach, M | 1 |
| Rein, DT | 1 |
| Mallmann, P | 1 |
| Prior, J | 1 |
| White, I | 1 |
| Fennelly, J | 1 |
| Beck, E | 1 |
| Schuster, M | 1 |
| Berg, A | 1 |
| Jäger, W | 1 |
| Wildt, L | 1 |
| Lang, N | 1 |
| Kaldor, JM | 1 |
| Day, NE | 1 |
| Pettersson, F | 1 |
| Clarke, EA | 1 |
| Pedersen, D | 1 |
| Mehnert, W | 1 |
| Bell, J | 1 |
| Høst, H | 1 |
| Prior, P | 1 |
| Karjalainen, S | 1 |
| Masding, J | 1 |
| Sarkar, TK | 1 |
| White, WF | 1 |
| Barley, VL | 1 |
| Chawla, SL | 1 |
| Boesen, E | 1 |
| Rostom, AY | 1 |
| Menday, AP | 1 |
| Kühnle, H | 1 |
| Grospietsch, G | 1 |
| Rümelin, B | 1 |
| Knappe, G | 1 |
| Temme, D | 1 |
| Hinney, B | 1 |
| Aabo, K | 1 |
| Hald, I | 1 |
| Hørbov, S | 1 |
| Dombernowsky, P | 1 |
| Hansen, HH | 1 |
| Lundvall, F | 1 |
| Nielsen, NC | 1 |
| Sørensen, BL | 1 |
| Shershah, S | 1 |
| Enig, B | 1 |
| Ersbøll, J | 1 |
| Keiding, N | 1 |
| Larsen, SO | 1 |
| Philip, P | 1 |
| Schultz, H | 1 |
| Duncan, ID | 1 |
| Clayton, LA | 1 |
| Armstrong, JG | 1 |
| Vortel, V | 1 |
| Peychl, L | 1 |
| Hartwich, G | 1 |
| Butzler, W | 1 |
| Czerniak, P | 1 |
| Zari, A | 1 |
| Visfeldt, J | 1 |
| Lundwall, F | 1 |
| Cerný, V | 1 |
| Sándor, L | 1 |
| Winkler, A | 1 |
| Ujházy, V | 1 |
| Uhrínová, M | 1 |
| Petrek, C | 1 |
| Siracký, J | 1 |
5 reviews available for busulfan and Cancer of Ovary
| Article | Year |
|---|---|
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Busulfan; Carcinoma, Ovar | 2016 |
Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Dose-R | 2013 |
High-dose alkylating agent therapy: a review of clinical experiences.
Topics: Alkylating Agents; Busulfan; Carcinoma, Bronchogenic; Carmustine; Dose-Response Relationship, Drug; | 1984 |
New drugs and experimental approaches in ovarian cancer treatment.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Aziridines; Benzoquinones; Busulfan; | 1984 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplat | 2002 |
12 trials available for busulfan and Cancer of Ovary
| Article | Year |
|---|---|
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolog
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu | 2009 |
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.
Topics: Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents, Alkylating; Busulfan; Constipation | 2012 |
A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CA-125 Antigen; Carboplati | 2006 |
A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation.
Topics: Abdomen; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical | 1984 |
Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Trans | 1995 |
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; | 1996 |
Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Carcinoma; Cisplati | 1998 |
Treosulfan as an effective second-line therapy in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Middle Aged; Neoplasm Recu | 1998 |
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Female; Humans; Le | 2002 |
Leukemia following chemotherapy for ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studie | 1990 |
Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Female; Humans; In | 1990 |
A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Tria | 1985 |
32 other studies available for busulfan and Cancer of Ovary
| Article | Year |
|---|---|
Treosulfan in platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Middle | 2021 |
Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; | 2015 |
Chemotherapy: Topotecan or treosulfan--that is the question.
Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance; D | 2009 |
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Drug Resistance, | 2010 |
Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic | 2002 |
Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Femal | 2003 |
Evaluation of chemotherapy in ovarian and cervical cancer by tissue culture methods.
Topics: Antineoplastic Agents; Busulfan; Female; Humans; Mechlorethamine; Neoplasms; Nitrogen Mustard Compou | 1959 |
[CYTOSTATIC THERAPY].
Topics: Antineoplastic Agents; Breast Neoplasms; Busulfan; Chlorambucil; Colchicine; Cyclophosphamide; Femal | 1964 |
FURTHER OBSERVATIONS ON LATE SOMATIC EFFECTS OF RADIOMIMETIC CHEMICALS AND X-RAYS IN MICE.
Topics: Aging; Busulfan; Cataract; Female; Humans; Leukemia; Leukemia, Myeloid; Longevity; Lung Neoplasms; L | 1965 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2004 |
The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Combined Modality Thera | 2005 |
Advanced ovarian cancer.
Topics: Alkylating Agents; Busulfan; Female; Humans; Ovarian Neoplasms | 1980 |
Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).
Topics: Adult; Aged; Busulfan; Chromosome Aberrations; Female; Humans; Leukemia; Middle Aged; Neoplasms, Mul | 1980 |
Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea | 1994 |
Drug resistance in ovarian cancer - the role of p53.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Co | 1998 |
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; | 1998 |
Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Busulfan; Do | 2000 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycyt | 2002 |
Addisonian syndrome associated with treosulfan.
Topics: Addison Disease; Busulfan; Cystadenocarcinoma; Female; Humans; Middle Aged; Ovarian Neoplasms | 1978 |
Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Busulfan; Cystadenocarcinoma; Female; Humans; Middle Aged; Ovarian Neop | 1977 |
[Ototoxicity of cisplatin chemotherapy in patients with ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Busulfan; Cisplatin; Dose-Res | 1991 |
[Postoperative therapy of epithelial ovarian cancer at the Göttingen University Gynecologic Clinic. A retrospective analysis of 82 patients 1981-1984].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Combined Modality | 1986 |
Treatment by combined chemotherapy for recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Cystadenocarcinoma; Female; Hum | 1985 |
[Has alteration of the postoperative treatment of ovarian cancer affected the survival rate? Assessment of a 7 year period].
Topics: Busulfan; Denmark; Female; Humans; Middle Aged; Ovarian Neoplasms; Radiation Dosage | 1985 |
Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Topics: Acute Disease; Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Prot | 1985 |
Combination chemotherapy of ovarian carcinoma with cisplatinum and treosulfan--a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Drug Evaluation; Female; | 1985 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
[2 cases of acquired latent focal toxoplasmosis of the brain in a cytostatic and corticosteroid treated neoplastic disease].
Topics: Autopsy; Brain; Brain Diseases; Busulfan; Female; Focal Infection; Glycine; Humans; Leukemia, Myeloi | 1970 |
[Secondary tumors in hemoblastoses during cytostatic treatment].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Bronchial Neoplasms; Busulfan; Carcinoma; Chlo | 1971 |
[Combined chemo-radionuclide therapy of cancer (complexotherapy)].
Topics: Antineoplastic Agents; Busulfan; Female; Gold Isotopes; Humans; Male; Middle Aged; Ovarian Neoplasms | 1971 |
Alteration of karyotypic profiles in human cancerous effusion following treatment with antineoplastic drug.
Topics: Adenocarcinoma; Ascitic Fluid; Busulfan; Chromosomes; Female; Humans; Karyotyping; Lymphatic Metasta | 1970 |
Mannitol-busulphan in advanced ovary carcinoma.
Topics: Adult; Aged; Busulfan; Female; Humans; Mannitol; Middle Aged; Ovarian Neoplasms | 1966 |